Antiplatelet Therapy for Secondary Stroke Prevention: 2012 Focused Update of Korean Clinical Practice Guidelines for Stroke.
- Author:
Tai Hwan PARK
1
;
Min Ky KIM
;
Hyung Geun OH
;
Mi Sun OH
;
Kyung Ho YU
;
Keun Sik HONG
;
Hee Joon BAE
;
Sun Uck KWON
;
Joung Ho RHA
;
Ji Hoe HEO
;
Chang Wan OH
;
Byung Chul LEE
;
Byung Woo YOON
Author Information
1. Department of Neurology, Seoul Medical Center, Seoul, Korea.
- Publication Type:Practice Guideline ; Review ; Clinical Trial
- Keywords:
Practice guideline;
Stroke;
Secondary prevention;
Cilostazol;
Aspirin
- MeSH:
Aspirin;
Cerebral Infarction;
Hemorrhage;
Humans;
Ischemic Attack, Transient;
Myocardial Infarction;
Secondary Prevention;
Stroke;
Tetrazoles;
Writing
- From:Korean Journal of Stroke
2012;14(1):1-5
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Writing Committee of Korean clinical practice guidelines for secondary prevention of stroke has reviewed recent randomized controlled trials of cilostazol published after the first edition of Korean clinical practice guidelines that considered evidences published before June 2007. Two clinical trials and 1 meta-analysis which compared cilostazol directly with aspirin in the prevention of stroke in patients with cerebral infarction or transient ischemic attack (TIA) were identified and included for the current guideline update. Review of findings indicates that cilostazol as compared to aspirin achieved a greater reduction of stroke as well as composite vascular events of stroke, myocardial infarction, and vascular death. For safety, cilostazol was associated with fewer major bleeding events than aspirin. Accordingly, new recommendations for cilostazol are made for prevention of stroke in the setting of noncardioembolic stroke or TIA. Changes in the guidelines necessitated by new evidences will be continuously reflected in future guidelines.
